Compare NHP & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NHP | ODTX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2012 | 2025 |
| Metric | NHP | ODTX |
|---|---|---|
| Price | $16.65 | $25.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 654.1K | 131.3K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.09 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,279,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.68 | $15.10 |
| 52 Week High | $17.46 | $28.00 |
| Indicator | NHP | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.42 | 68.99 |
| Support Level | $14.54 | $19.84 |
| Resistance Level | $17.22 | N/A |
| Average True Range (ATR) | 0.63 | 1.84 |
| MACD | -0.00 | 0.48 |
| Stochastic Oscillator | 54.55 | 73.90 |
National Healthcare Properties Inc is a publicly registered real estate investment trust. It is focused on acquiring, owning, and managing a diversified portfolio of healthcare real estate assets focused on senior housing operating properties (SHOP) and outpatient medical facilities (OMF) in the United States. The company operates in two reportable business segments: SHOP and OMF. The SHOP segment consists of assisted living communities, memory care communities and independent living communities, which are focused on needs-based assisted living and memory care. The OMF segment consists of physicians' offices and examination rooms, hospitals, pharmacies, hospital ancillary service space and other outpatient services. The majority of revenue is derived from the SHOP segment.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.